Research Insight
21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment
New findings from the longest assessment of any MS-specific treatment show that patients treated earlier with Betaferon® (interferon beta-1b) had a 39.3% relative reduced risk in mortality for the time since randomization in the study (P=0.027), compared with patients...
Research Insight
Sanofi-aventis announced the results from the two year phase III TEMSO study of teriflunomide
Sanofi-aventis announced the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly...
Research Insight
Novartis Phase III study of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumors showing potential benefit
A Novartis Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR® (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced neuroendocrine tumors (NET) compared to taking...
Research Insight
Afatinib (BIBW 2992*) triples progression free survival in phase III study in lung cancer patients
Boehringer Ingelheim announced today promising results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35 th European Society for Medical Oncology (ESMO) Congress in Milan, Italy. Results from the “LUX-Lung 1” trial...
Research Insight
The GRACE study has significant implications for inclusion of women in clinical trials
Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment-experienced adult women with HIV-1 to examine gender differences in response to HIV therapy....
Research Insight
Novartis study shows Onbrez® Breezhaler® is superior to salmeterol in reducing breathlessness for patients with COPD
Results of the Phase III INSIST study show that Onbrez® Breezhaler® (indacaterol) given once-daily is significantly better at improving lung function and reducing breathlessness than twice-daily salmeterol, one of the current mainstays of treatment for patients with chronic obstructive...
Research Insight
Genetic substudy shows fewer major cardiovascular events with ticagrelor (brilinta) regardless of relevant genetic variability in ACS patients
A new genetic substudy of PLATO showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes (ACS) patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA™), were...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read